Page 2 - Therapeutics Development News Today

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma ALLO-316 Illustrates Proof-of-Concept in RCC and...

Building a premier biotech hub in Birmingham Station 41 is a “great stride” toward a new center of commercialization Story by Matt Windsor | Photos by...

The new sensor completes its task in just 30 minutes but also proves to be cost-effective. Promising for multiple sclerosis, diabetes, Alzheimers treatments.

This development marks a significant milestone for 23andMe, a company that has been in the spotlight for security breaches in the past.

19.12.2023 - Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational antibody targeting CD200R1 A second potentially efficacious dose level to characterize safety and ... Seite 1

The ongoing review of the EU Pharmaceutical Legislation is looking at recalibrating IP incentives. Intellectual Property fuels medical innovations from the research bench to the patient’s bedside.

/PRNewswire/ -- The "Advances in Mitochondrial Disease Management" report has been added to ResearchAndMarkets.coms offering. This study identifies diverse...

Have you ever wondered how scientists delve into the intricate details of cellular behavior, unraveling the mysteries of life at a microscopic level? Flow cytometry is a ground-breaking technology that has transformed the field of biomedical research. What technological marvels paved the way for our invention?Flow cytometry was formed as a result of a fascinating

Operator: Hello, and welcome to 23andMes Fiscal Year 2024 Second Quarter Financial Results Conference Call. As a reminder, this call is being recorded.

23andMe presented data from the now completed dose escalation phase, and pharmacokinetic / pharmacodynamic (PK/PD) cohorts at the Society for Immunotherapy of Cancer Annual Meeting 2023